Cargando…

Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis

OBJECTIVES: The effectiveness of TNF inhibitors in RA has been shown to be affected by obesity. No such effect has been found for abatacept and rituximab, while for tocilizumab results are ambiguous. Additionally, it remains unresolved whether sex is an effect modifier for obesity. We investigated t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schäfer, Martin, Meißner, Yvette, Kekow, Jörn, Berger, Sylvia, Remstedt, Sven, Manger, Bernhard, Listing, Joachim, Strangfeld, Anja, Zink, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382601/ https://www.ncbi.nlm.nih.gov/pubmed/31745566 http://dx.doi.org/10.1093/rheumatology/kez535

Ejemplares similares

Corrigendum to: Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis
por: Schäfer, Martin, et al.
Publicado: (2020)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015)

Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis
por: Meissner, Yvette, et al.
Publicado: (2016)

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort
por: Baganz, Lisa, et al.
Publicado: (2017)

Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT
por: Schäfer, Martin, et al.
Publicado: (2020)

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2023)

Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort
por: Meissner, Y, et al.
Publicado: (2017)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2020)

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register
por: Listing, Joachim, et al.
Publicado: (2006)

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
por: Strangfeld, Anja, et al.
Publicado: (2010)

Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT
por: Gerhold, Kerstin, et al.
Publicado: (2015)

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
por: Strangfeld, A, et al.
Publicado: (2017)

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
por: Richter, A, et al.
Publicado: (2016)

Evaluation of the RABBIT Risk Score for serious infections
por: Zink, A, et al.
Publicado: (2014)

Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases
por: Albrecht, Katinka, et al.
Publicado: (2016)

Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3-Year Followup of a German Biologics Register
por: Richter, Adrian, et al.
Publicado: (2014)

Complex genetic predisposition in adult and juvenile rheumatoid arthritis
por: Miterski, Bianca, et al.
Publicado: (2004)

Neues aus dem RABBIT-Register
por: Meißner, Yvette, et al.
Publicado: (2021)

Long-term persistence and effects of fetal microchimerisms on disease onset and status in a cohort of women with rheumatoid arthritis and systemic lupus erythematosus
por: Kekow, Marianne, et al.
Publicado: (2013)

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
por: Mercer, Louise K, et al.
Publicado: (2017)

Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis
por: Schotte, Heiko, et al.
Publicado: (2015)

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
por: Mercer, Louise K, et al.
Publicado: (2017)

Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets
por: Alunno, Alessia, et al.
Publicado: (2017)

Molecular signatures of rheumatoid arthritis characterized by transcriptome and proteome analysis
por: Glocker, MO, et al.
Publicado: (2005)

Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020
por: Albrecht, Katinka, et al.
Publicado: (2023)

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
por: Strangfeld, A, et al.
Publicado: (2011)

The Cytokine Network in Rheumatoid Arthritis: Definition of TNFα as a Therapeutic Target
por: Feldmann, Marc
Publicado: (1996)

Going Further: Comprehensive Disease Control of Rheumatoid Arthritis, Targeting Cytokines and Chemokines
por: Chavarria-Avila, Efrain, et al.
Publicado: (2021)

Modulation of the gene expression pattern in peripheral blood mononuclear cells by biologicals in rheumatoid arthritis
por: Kekow, J, et al.
Publicado: (2003)

Targeting Probiotics in Rheumatoid Arthritis
por: Bungau, Simona Gabriela, et al.
Publicado: (2021)

Cytokines as Biomarkers in Rheumatoid Arthritis
por: Burska, Agata, et al.
Publicado: (2014)

Hepatitis-E-Virus-Infektion bei einem Patienten mit rheumatoider Arthritis unter Baricitinib-Therapie
por: Valor-Méndez, Larissa, et al.
Publicado: (2021)

Future therapeutic targets in rheumatoid arthritis?
por: Cheung, Tommy Tsang, et al.
Publicado: (2017)

Metabolites as drivers and targets in rheumatoid arthritis
por: Hanlon, Megan M, et al.
Publicado: (2021)

Ferroptosis as an emerging target in rheumatoid arthritis
por: Zhao, Hui, et al.
Publicado: (2023)

Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis
por: Kondo, Naoki, et al.
Publicado: (2021)

Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
por: Koczan, Dirk, et al.
Publicado: (2008)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow, Joern, et al.
Publicado: (2012)

Implementing an automated monitoring process in a digital, longitudinal observational cohort study
por: Lindner, Lisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u3b2tf1133qlgr8gm02n8ha4eq